Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ferric Carboxymaltose in Elderly Acute Coronary Syndrome Patients
2025-522421-36-00Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria Hospital Clínico San Carlos
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute coronary syndrome (ACS) and iron deficiency anemia (IDA) comparing Intravenous ferric carboxymaltose with Control (standard of care without intravenous iron) (2 arms). Planned start Dec 2025; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
acute coronary syndrome (ACS)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2025-522421-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522421-36-00.